saplin

UTI - Mid Cap Fund

UTI - Mid Cap Fund (Direct, Growth): saplin Score 4.3/10 (Weak) among 33 Mid Cap funds. 3Y return 11.6% a year vs 16.4% category median, expense ratio 1.27%. Uneven returns hold this fund back. NAV ₹347.78 on 11 Nov 2026.

Loading the full analysis…

Questions about UTI - Mid Cap Fund

What is the expense ratio of UTI - Mid Cap Fund?

The Direct plan's total expense ratio is 1.27% a year, against a median of 0.94% for mid cap funds. The Regular plan costs more because it pays a distributor's commission.

Who manages UTI - Mid Cap Fund?

Vishal Chopda (since 16 Jun 2025).

What are the top holdings of UTI - Mid Cap Fund?

Coforge 3.54%, Blue Star 2.81%, AU Small Finance Bank 2.47%, Info Edge (India) 2.31%, Aurobindo Pharma 2.18% of the portfolio, as of 31 Oct 2026.

What returns has UTI - Mid Cap Fund given?

1 year: 1.8% (category median 4.9%); 3 years: 11.6% a year (category median 16.4%); 5 years: 10.6% a year (category median 14.3%). Past returns do not predict future ones.

How big is UTI - Mid Cap Fund?

About ₹12,421 cr (AMFI's average for the latest quarter).

How does UTI - Mid Cap Fund score?

4.3 out of 10 (Weak) on the saplin Score, which rates a fund against its own category on returns, risk, consistency, cost and its manager. See the methodology for how it is worked out.

More on UTI - Mid Cap